Mason-based Mira Precision Health launched the ToxNav® Advantage™ at the 2026 ASCO® GI Cancers Symposium. The launch brings life-changing technology to the U.S. and represents more than a decade of clinical research and strong partnership with Oxford Cancer Biomarkers. This launch is another example of the strengths of the Mason Living Lab, which engages city residents and employees as participants to advance new technology, differentiating Mason’s position in the Midwest.
Read more from Mira Precision Health about their industry-changing launch.
Read more